| Hematology | ||||||
| No. | Study Title | Principle Investigator | Sponsor | Type | Recruiting | Study status |
| 1 | REACH 3 study: A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft vs host disease after allogenic stem cell transplantation. | Dr. Husam Abu Jazar | Novartis | Clinical Trial | No | Ongoing |
| 2 | Safety and Efficacy of Dasatinib 50 mg in First Line Treatment of Early Chronic Phase Chronic Myeloid Leukemia. | Dr. Kamal Al-Rabi | Hikma | Clinical Trial | Yes | Ongoing |
| 3 | A phase II, open-label, single arm study to evaluate the safety, efficacy, and pharmacokinetics of twice daily midostaurin (PKC412) combined with standard chemotherapy and as a single agent post-consolidation therapy in children with untreated FLT3-mutated AML. | Dr. Mayada Abu Shanab | Novartis | Clinical Trial | No | Pending |
| 4 | CAR T - NHL : A phase II Study of CART Cell (MB-CART19.1) in Patients with Relapsed or Refractory CD19 Positive NHL | Dr. Khalid Halahleh | KHCC | |||
| 5 | CPKC412A2218 Novartis: A phase II, open-label, single arm study to evaluate the safety, efficacy, and pharmacokinetics of twice daily midostaurin (PKC412) combined with standard chemotherapy and as a single agent post-consolidation therapy in children with untreated FLT3-mutated AML | Dr. Mayada Abu Shanab | Novartis | |||
| 6 | Ferinject: The Role of Iron Therapy Administration in optimizing Pre-operative anemia among Oncology Patients before Elective Major Surgery. A Clinical Trial Study | Dr. Mahmoud Al Masri | KHCC | |||
| 7 | CAR T – ALL: MB-CART19.1 in patient with relapsed - refractory CD19 positive B cell acute lymphoblastic leukemia: A feasibility study | Dr. Zaid Abdelrahman & Dr. Hasan Hashem | KHCC | |||
| 8 | DOMAIN: A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients with Diffuse Large B-Cell Lymphoma in the MEA Region | Dr. Mohammad Ma'koseh | AstraZeneca | |||
| 9 | HOPE: A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Clinical Study to Assess Efficacy and Safety of Ropeginterferon alfa-2b (P1101) in Adult Patients with Pre-fibrotic/Early Primary Myelofibrosis or Overt Primary Myelofibrosis at Low or Intermediate-1 Risk According to DIPSS Plus (HOPE-PMF): The Core Study and Its Extension Study | Dr. Waleed Da'na | PharmaEssentia | |||